title: [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
abstract: Regarding to the role of cytokines in ethiology of rheumatoid arthritis, the treatment with anti-TNFalpha is coming to be reasonable in early aggressive rheumatoid arthritis. Studies of etanercept in early stage of disease indicate the sustained efficacy and decreased rate of radiographic progression with significant improvement of life quality.
authors.affiliation: Odsjek za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Split, Soltanska 1, 2100 Split.
authors.forename: Dusanka Martinović
authors.initials: DM
authors.lastname: Kaliterna
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept